Rhythm Pharmaceuticals reported earnings on August 4 and the options market reacted with one of the most aggressive bull shifts of the past year — making positioning the real story this week, not the result itself.
The clearest signal is in call activity. The put/call ratio collapsed to 0.35 on August 4, more than four standard deviations below its 20-day average of 0.48. That is the most extreme call-heavy reading RYTM has seen in at least a year, with the 52-week low sitting at 0.08 and the high at 1.07 — the current level puts this squarely at the bullish end of the range. The move is abrupt: the PCR had been tracking in a tight band around 0.49 for weeks before it broke sharply lower on results day. That kind of single-session rotation into calls points to targeted upside positioning, not a slow drift in sentiment.
Short interest tells a more complicated story. Bears are meaningfully present — 14.2% of the free float is short, a figure that has climbed roughly 11.5% over the past month and about 15% since early July when shares short jumped from the ~8.2 million range to above 9.4 million. The stock fell 7.3% on the month to $105.78, which gives some context for why fresh shorts built. Yet the borrow market is far from stressed. Availability is extremely loose at over 2,000% — meaning roughly twenty shares are available for every one currently borrowed — and has actually widened back toward recent highs after tightening sharply to 930% on July 13. Cost to borrow, despite rising 11.5% on the week, is just 0.49%: essentially free. The short score of 63.5 is steady and has barely moved over ten sessions. The picture is shorts rebuilding on price weakness, but with zero squeeze pressure and no urgency in the lending market.
The Street reacted positively to the print. Multiple firms lifted targets on August 5 alone. RBC Capital raised its target to $155 from $141, the largest single move among this week's changes. Citigroup nudged to $143, and Citizens moved to $160. JP Morgan, which only initiated coverage on July 27 with an Overweight and a $145 target, is now already below the post-earnings consensus direction. The mean target across the group is $140, which, against the current price of $105.78, implies roughly 32% upside — meaningful for a commercial-stage biotech. The analyst recommendation divergence factor ranks in the 92nd percentile of the ORTEX universe, confirming the Street is unusually aligned in its bullishness. The forward EPS estimate trend ranks in the 94th percentile for year-on-year increase, reflecting the commercial ramp of IMCIVREE. Price-to-book has expanded to roughly 11x over the past week, consistent with a valuation re-rating post-earnings.
The bull case centres on setmelanotide's continued clinical momentum — BMI reductions in the Phase 2 obesity/hyperphagia study, positive interim data in Prader-Willi syndrome, and prospective launches in the EU and Japan. The bear case is not about the science; it is operational. Payer adoption has averaged six months, dilution risk lingers, and competition from Vykat XR is real. The stock is down 7% over the past month despite the earnings pop, reflecting the tension between clinical progress and commercial execution pace.
Among correlated peers, ACAD gained 6% on the day and 4.4% on the week, while DNLI added 4.4% on the day. SRRK and AVTX lagged, both down on the week. RYTM's 2.9% single-day gain on August 4 was broadly in line with the peer group bounce, suggesting sector tailwinds rather than a RYTM-specific re-rating were partly at work.
The next key watch is whether the call-heavy positioning from earnings day persists or fades in the sessions ahead — a sustained low PCR would confirm durable conviction from options traders, while a reversion toward 0.48 would suggest the move was event-driven noise.
See the live data behind this article on ORTEX.
Open RYTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
